Top Stories
The CSF-1R inhibitor demonstrated a 56% response rate in Phase III, alongside improvements in pain and physical function.
The companies first entered into a deal in 2024, under which AstraZeneca gained exclusive rights to Omniose's bioconjugation platform.
The once-daily atypical antipsychotic significantly improved manic symptoms and overall illness severity versus placebo at week 3.
The Danish pharma attributed the upgrade in part to migraine drug Vyepti's continued "strong performance" in the US.
Funnel Biosciences launched in February with support from investor Yijing Capital.
Conference News
Oral presentation at ACR Convergence uncovers the role of the CD40 pathway in myositis and potential therapeutic benefit of ABX1200, a novel CD71-Centyrin CD40-siRNA conjugatePHILADELPHIA, Nov. 10, 20...
Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeksData shared in oral presentation at AASLD The Liver Mee...
Oral presentation includes data demonstrating armored allogeneic CD19 CAR T cells elicited a nearly 20-fold greater expansion than unarmored cells and more sustained B-cell depletion in humanized mice...
Updated safety data of 36 patients treated with FT819 across three regimens and four autoimmune disease indications with no dose-limiting toxicities continues to be favorable100% (3 of 3) of extrarena...
Myeloid-directed JAK inhibition aims to control inflammation while preserving adaptive immune function and reducing infection riskJAK-dendranibs demonstrate efficacy comparable to baricitinib and sign...
